Press Releases

Date Title and Summary Additional Formats
Toggle Summary Aravive and 3D Medicines Announce Strategic Collaboration to Develop and Commercialize AVB-500 in Greater China
Aravive to Receive $12 Million Signing Payment , u p to an Additional $20 7   M illion in Future Milestone Payments plus Tiered Royalties 3D Medicines to Lead Clinical Development and Commercialization of AVB-500 in Greater China HOUSTON and SHANGHAI, China , Nov.
View HTML
Toggle Summary Aravive Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
Company expects to initiate pivotal trial of AVB-500 in Platinum Resistant Ovarian Cancer during fourth quarter 2020/first quarter 2021, based on Phase 1b results On-track to initiate Phase 1b/2 trial of AVB-500 in Clear Cell Renal Cell Carcinoma during fourth quarter 2020 Expanded Board of
View HTML
Toggle Summary Aravive Appoints Michael W. Rogers to Board of Directors
Strengthens Advisory Team with Industry Veteran as Company Advances AVB-500 in Platinum Resistant Ovarian Cancer (PROC) HOUSTON , Sept. 17, 2020 (GLOBE NEWSWIRE) -- Aravive , Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing transformative therapeutics, today announced that
View HTML
Toggle Summary Aravive Appoints Reshma Rangwala, M.D., Ph.D., as Chief Medical Officer
HOUSTON , Sept. 15, 2020 (GLOBE NEWSWIRE) -- Aravive , Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced the appointment of industry veteran and oncologist, Reshma Rangwala , M.D., Ph.D., as Chief Medical Officer. “We are honored that Dr.
View HTML
Toggle Summary Aravive to Participate in Upcoming Virtual Investor Conferences in September
HOUSTON , Sept. 08, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that the Company will present and conduct one-on-one meetings at the following two virtual investor conferences in September: Cantor
View HTML
Toggle Summary Aravive Strengthens Leadership Team with Appointment of Key Industry Veterans
Expands Clinical Development and Oncology Expertise as Company Advances AVB-500 in Platinum Resistant Ovarian Cancer HOUSTON , Aug. 27, 2020 (GLOBE NEWSWIRE) --  Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing transformative therapeutics, today announced the
View HTML
Toggle Summary Aravive Reports Second Quarter 2020 Financial Results and Provides Recent Corporate Updates
Successfully completed Phase 1b trial of AVB-500 in Platinum Resistant Ovarian Cancer with encouraging clinical data showing 60% ORR in the subpopulation that has not previously been treated with bevacizumab On-track to discuss the potential pivotal trial of AVB-500 with FDA this year On-track to
View HTML
Toggle Summary Aravive to Participate in Upcoming Virtual Investor Conferences in August
HOUSTON , July 30, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that the Company will present and conduct one-on-one meetings at the following three virtual investor conferences in August: William
View HTML
Toggle Summary Aravive Announces Successful Completion of Phase 1b Trial Evaluating AVB-500 in Platinum Resistant Ovarian Cancer
Identifies Recommended Phase 2 Dose for Continued Clinical Development of AVB-500  in Platinum Resistant Ovarian Cancer Aravive to Host Conference Call and Webcast Today at 8:30 a.m. ET HOUSTON , July 23, 2020 (GLOBE NEWSWIRE) -- Aravive , Inc. (Nasdaq: ARAV), a clinical-stage oncology company
View HTML
Toggle Summary Aravive Added to the Russell 2000® and Russell 3000® Indexes
HOUSTON , June 30, 2020 (GLOBE NEWSWIRE) -- Aravive , Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis, today announced that the Company has been added to the Russell
View HTML